title: [Clinical experience with the treatment of metastatic renal cell carcinoma with subcutaneous interleukin-2r (IL-2r) and interferon Alpha-2b (IFN Alfa-2b)].
abstract: This work presents our recent clinic experience in the treatment of advanced RCC with IL-2 in association to alpha IFN given subcutaneously. Fifteen patient with histologically confirmed advanced RCC and measurable lesions were entered in the study. Patients were treated in cycles of 7 weeks at a IL-2 dose of 4.8 million IU/m2 (induction phase)-2.4 million IU/m2 (maintenance phase) every 12h five days a week and alpha IFN: 6 million IU/m2 every 24h three days a week, and were afterwards evaluated for response. Responders with localized residual bulk underwent rescue surgery. Seven patient has objective response (3 complete, 2 partial and 2 stable responses). The complete responses were stable and lasted 36 m, 14 m and 8 m, and global survival was of 14.6 m (3-36 m). All patients had toxicity at various degrees but WHO grade II was not exceeded at any time. The association of IL-2 and alpha IFN 2b given subcutaneously, appears to have antitumoral activity against advanced RCC with durable responses and in a proportion similar to other associations in intravenous administration, but with lower systemic toxicity. Surgical resection of residual bulk can be beneficial in selected patient with partial response.
authors.affiliation: Servicio de Urología, Clínica Puerta de Hierro, Madrid.
authors.forename: C
authors.initials: C
authors.lastname: Olivier
authors.forename: J
authors.initials: J
authors.lastname: Carballido
authors.forename: A H
authors.initials: AH
authors.lastname: Lao
authors.forename: A
authors.initials: A
authors.lastname: Gimeno
authors.forename: C
authors.initials: C
authors.lastname: Martín
authors.forename: D
authors.initials: D
authors.lastname: Renjifo
authors.forename: L M
authors.initials: LM
authors.lastname: Ondina
authors.forename: L
authors.initials: L
authors.lastname: Manzano
authors.forename: M
authors.initials: M
authors.lastname: Alvarez-Mon
mesh_terms: D000328:Adult; D000368:Aged; D002292:Carcinoma, Renal Cell / Q000556:secondary / Q000628:therapy*; D005260:Female; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D007279:Injections, Subcutaneous; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D007376:Interleukin-2 / Q000627:therapeutic use*; D007680:Kidney Neoplasms / Q000473:pathology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins
chemical_list: D007155:Immunologic Factors; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D007376:Interleukin-2; D011994:Recombinant Proteins
vernacular_title: Experiencia clínica en el tratamiento del carcinoma de células renales metastático con interleucina-2r (IL-2r) e interferón alfa 2b (IFN alfa 2b) por vía subcutánea.